{"id":"W2905822848","doi":"10.1016/j.ejca.2018.11.018","title":"An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre","funders":"Merck Sharp and Dohme; EUSA Pharma; Eisai; Genentech; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Chugai Pharmaceutical; Amgen; Pfizer; Bristol-Myers Squibb; F. Hoffmann-La Roche","keywords":"Vemurafenib; Medicine; Internal medicine; Tolerability; Melanoma; Metastatic melanoma; Dacarbazine; Oncology; Clinical trial; Population; Surgery; Adverse effect; Chemotherapy; Cancer research; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000568901,0.0001466621,0.0003541755,0.000139779,0.0000560208,0.0000422916,0.0002986209,0.00001518457,0.000009827004],"category_scores_gemma":[0.00003654552,0.0001057358,0.0000240921,0.0002829396,0.00004971294,0.00002166043,0.0001034417,0.00008631797,7.148737e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002512767,"about_ca_system_score_gemma":0.00007670813,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005492609,"about_ca_topic_score_gemma":0.0003769507,"domain_scores_codex":[0.9983495,0.0005083318,0.0005206722,0.0002338499,0.0002205539,0.0001670794],"domain_scores_gemma":[0.9987763,0.0000122572,0.0004996838,0.000226561,0.0003719068,0.0001132676],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003844666,0.001528687,0.9350597,0.00007274269,0.001539504,0.0001924559,0.001353592,0.0002691738,0.05059719,0.000004377265,0.0000106852,0.005527233],"study_design_scores_gemma":[0.01434337,0.01384118,0.9596348,0.0002479593,0.001212529,0.00001829508,0.0009834666,0.0002518913,0.009084357,3.187409e-7,0.0001621288,0.0002196474],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9988511,0.000196418,0.0003624159,0.000006385214,0.00008105832,0.0003530101,0.00002628116,0.000002521251,0.0001208456],"genre_scores_gemma":[0.99914,0.00001442926,0.000702117,0.00001275009,0.00007842339,0.000002709538,0.00001227088,0.00002206985,0.0000152101],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04151283,"threshold_uncertainty_score":0.4311783,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02297751324771618,"score_gpt":0.2802544449555863,"score_spread":0.2572769317078701,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}